{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:57:26Z","timestamp":1792796246732,"version":"4.5.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004869","name":"Westf\u00e4lische Wilhelms-Universit\u00e4t M\u00fcnster","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004869","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s13311-021-01175-7","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T17:02:51Z","timestamp":1641574971000},"page":"729-740","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Neonatal Fc Receptor\u2013Targeted Therapies in Neurology"],"prefix":"10.1016","volume":"19","author":[{"given":"Christopher","family":"Nelke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Spatola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina B.","family":"Schroeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Wiendl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan D.","family":"L\u00fcnemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-021-01175-7_bib1","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1007\/s13311-021-01175-7_bib2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-021-01175-7_bib3","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41582-021-00547-z","article-title":"Getting specific: targeting Fc receptors in myasthenia gravis","volume":"17","author":"L\u00fcnemann","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-021-01175-7_bib4","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/337184a0","article-title":"An Fc receptor structurally related to MHC class I antigens","volume":"337","author":"Simister","year":"1989","journal-title":"Nature"},{"key":"10.1007\/s13311-021-01175-7_bib5","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/372336a0","article-title":"Crystal structure at 2.2 \u00c5 resolution of the MHC-related neonatal Fc receptor","volume":"372","author":"Burmeister","year":"1994","journal-title":"Nature"},{"key":"10.1007\/s13311-021-01175-7_bib6","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1073\/pnas.0708960105","article-title":"Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn","volume":"105","author":"Mezo","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"10.1007\/s13311-021-01175-7_bib7","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2174\/0929866523666160404125850","article-title":"The X-Ray Crystallographic structure of the human neonatal Fc receptor at acidic pH gives insights into pH-dependent conformational changes","volume":"23","author":"Mohammed","year":"2016","journal-title":"Protein Pept Lett"},{"key":"10.1007\/s13311-021-01175-7_bib8","doi-asserted-by":"crossref","first-page":"6246","DOI":"10.4049\/jimmunol.154.12.6246","article-title":"Requirement for a beta 2-microglobulin-associated Fc receptor for acquisition of maternal IgG by fetal and neonatal mice","volume":"154","author":"Israel","year":"1995","journal-title":"J Immunol"},{"key":"10.1007\/s13311-021-01175-7_bib9","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/eji.1830260327","article-title":"Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice","volume":"26","author":"Ghetie","year":"1996","journal-title":"Eur J Immunol"},{"key":"10.1007\/s13311-021-01175-7_bib10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1084\/jem.20021829","article-title":"The major histocompatibility complex\u2013related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan","volume":"197","author":"Chaudhury","year":"2003","journal-title":"J Exp Med"},{"key":"10.1007\/s13311-021-01175-7_bib11","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1073\/pnas.0600548103","article-title":"Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant \u03b22-microglobulin gene","volume":"103","author":"Wani","year":"2006","journal-title":"Proc Natl Acad Sci"},{"key":"10.1007\/s13311-021-01175-7_bib12","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jaci.2014.12.1937","article-title":"\u03b22-Microglobulin deficiency causes a complex immunodeficiency of the innate and adaptive immune system","volume":"136","author":"Ardeniz","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1007\/s13311-021-01175-7_bib13","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1021\/bi052628y","article-title":"Albumin Binding to FcRn: Distinct from the FcRn\u2212IgG Interaction","volume":"45","author":"Chaudhury","year":"2006","journal-title":"Biochemistry"},{"key":"10.1007\/s13311-021-01175-7_bib14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fimmu.2015.00039","article-title":"Selection of IgG variants with increased FcRn binding using random and directed mutagenesis: impact on effector functions","volume":"6","author":"Monnet","year":"2015","journal-title":"Front Immunol"},{"key":"10.1007\/s13311-021-01175-7_bib15","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.4049\/jimmunol.1401218","article-title":"Fc engineering of human IgG1 for altered binding to the neonatal Fc receptor aaffects Fc effector functions","volume":"194","author":"Grevys","year":"2015","journal-title":"J Immunol Author Choice"},{"key":"10.1007\/s13311-021-01175-7_bib16","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ab.2011.03.001","article-title":"Field flow fractionation for assessing neonatal Fc receptor and Fc\u03b3 receptor binding to monoclonal antibodies in solution","volume":"414","author":"Pollastrini","year":"2011","journal-title":"Anal Biochem"},{"key":"10.1007\/s13311-021-01175-7_bib17","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/intimm\/13.12.1551","article-title":"Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies","volume":"13","author":"Ober","year":"2001","journal-title":"Int Immunol"},{"key":"10.1007\/s13311-021-01175-7_bib18","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1369\/0022155417705095","article-title":"Distribution of FcRn across species and tissues","volume":"65","author":"Latvala","year":"2017","journal-title":"J Histochem Cytochem"},{"key":"10.1007\/s13311-021-01175-7_bib19","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1681\/ASN.V114632","article-title":"Characterization and localization of the neonatal Fc receptor in adult human kidney","volume":"11","author":"Haymann","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1007\/s13311-021-01175-7_bib20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1084\/jem.20020400","article-title":"Receptor-mediated immunoglobulin G transport across mucosal barriers in aadult life: functional expression of FcRn in the mammalian lung","volume":"196","author":"Spiekermann","year":"2002","journal-title":"J Exp Med"},{"key":"10.1007\/s13311-021-01175-7_bib21","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.immuni.2004.05.007","article-title":"Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells","volume":"20","author":"Yoshida","year":"2004","journal-title":"Immunity"},{"key":"10.1007\/s13311-021-01175-7_bib22","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1007\/s11095-013-1212-3","article-title":"Human and non-human primate intestinal FcRn expression and immunoglobulin G transcytosis","volume":"31","author":"Hornby","year":"2014","journal-title":"Pharm Res"},{"key":"10.1007\/s13311-021-01175-7_bib23","doi-asserted-by":"crossref","first-page":"G352","DOI":"10.1152\/ajpgi.00286.2005","article-title":"Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces","volume":"290","author":"Kim","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1007\/s13311-021-01175-7_bib24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/biom9080373","article-title":"Human FcRn tissue expression profile and half-life in PBMCs","volume":"9","author":"Fan","year":"2019","journal-title":"Biomolecules"},{"key":"10.1007\/s13311-021-01175-7_bib25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/intimm\/dxg018","article-title":"Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans","volume":"15","author":"Ward","year":"2003","journal-title":"Int Immunol"},{"key":"10.1007\/s13311-021-01175-7_bib26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0198-8859(00)00244-5","article-title":"Expression of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells","volume":"62","author":"Antohe","year":"2001","journal-title":"Hum Immunol"},{"key":"10.1007\/s13311-021-01175-7_bib27","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1208\/s12248-009-9129-9","article-title":"Investigation of the influence of FcRn on the distribution of IgG to the brain","volume":"11","author":"Garg","year":"2009","journal-title":"AAPS J"},{"key":"10.1007\/s13311-021-01175-7_bib28","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1073\/pnas.0700337104","article-title":"Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy","volume":"104","author":"Prabhat","year":"2007","journal-title":"Proc Natl Acad Sci"},{"key":"10.1007\/s13311-021-01175-7_bib29","doi-asserted-by":"crossref","unstructured":"Gan Z, Ram S, Vaccaro C, Ober RJ, Ward ES. Analyses of the recycling receptor, FcRn, in live cells reveal novel pathways for lysosomal delivery. Traffic. 2009 May;10(5):600\u201314. https:\/\/doi.org\/10.1111\/j.1600-0854.2009.00887.x. Epub 2009 Jan 24. PMID: 19192244; PM@@CI@@D: PMC2813311. Accessed 1 Nov 2021.","DOI":"10.1111\/j.1600-0854.2009.00887.x"},{"key":"10.1007\/s13311-021-01175-7_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax9586","article-title":"Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex\u2013mediated immune responses","volume":"5","author":"Blumberg","year":"2019","journal-title":"Sci Adv"},{"key":"10.1007\/s13311-021-01175-7_bib31","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.intimp.2018.11.040","article-title":"Generation of two high affinity anti-mouse FcRn antibodies: inhibition of IgG recycling in wild type mice and effect in a mouse model of immune thrombocytopenia","volume":"66","author":"Smith","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"10.1007\/s13311-021-01175-7_bib32","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00018-012-1100-8","article-title":"Cross-presentation of IgG-containing immune complexes","volume":"70","author":"Baker","year":"2013","journal-title":"Cell Mol Life Sci CMLS"},{"key":"10.1007\/s13311-021-01175-7_bib33","doi-asserted-by":"crossref","first-page":"9337","DOI":"10.1073\/pnas.0801717105","article-title":"Dependence of antibody-mediated presentation of antigen on FcRn","volume":"105","author":"Qiao","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"10.1007\/s13311-021-01175-7_bib34","doi-asserted-by":"crossref","first-page":"9927","DOI":"10.1073\/pnas.1019037108","article-title":"Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8\u2212CD11b+ dendritic cells","volume":"108","author":"Baker","year":"2011","journal-title":"Proc Natl Acad Sci"},{"key":"10.1007\/s13311-021-01175-7_bib35","doi-asserted-by":"crossref","DOI":"10.1177\/1756286421997381","article-title":"The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors","volume":"14","author":"Dalakas","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1007\/s13311-021-01175-7_bib36","article-title":"Intravenous immunoglobulin for myasthenia gravis","volume":"12","author":"Gajdos","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1007\/s13311-021-01175-7_bib37","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJM199901213400311","article-title":"Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases","volume":"340","author":"Yu","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-021-01175-7_bib38","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420986747","article-title":"VNTR2\/VNTR3 genotype in the FCGRT gene is associated with reduced effectiveness of intravenous immunoglobulin in patients with myasthenia gravis","volume":"14","author":"Su","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1007\/s13311-021-01175-7_bib39","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJMra1708712","article-title":"Antibody-mediated encephalitis","volume":"378","author":"Dalmau","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-021-01175-7_bib40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/ana.21050","article-title":"Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma","volume":"61","author":"Dalmau","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-021-01175-7_bib41","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-021-01175-7_bib42","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S1474-4422(10)70137-X","article-title":"Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series","volume":"9","author":"Lai","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-021-01175-7_bib43","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/ana.22307","article-title":"Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis","volume":"69","author":"Irani","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-021-01175-7_bib44","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1523\/JNEUROSCI.0167-10.2010","article-title":"Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis","volume":"30","author":"Hughes","year":"2010","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"10.1007\/s13311-021-01175-7_bib45","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1093\/brain\/aww208","article-title":"Human cerebrospinal fluid monoclonal N-methyl-D-aspartate receptor autoantibodies are sufficient for encephalitis pathogenesis","volume":"139","author":"Kreye","year":"2016","journal-title":"Brain J Neurol"},{"key":"10.1007\/s13311-021-01175-7_bib46","doi-asserted-by":"crossref","first-page":"18161","DOI":"10.1523\/JNEUROSCI.3506-13.2013","article-title":"Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors","volume":"33","author":"Ohkawa","year":"2013","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"10.1007\/s13311-021-01175-7_bib47","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/brain\/awu310","article-title":"Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice","volume":"138","author":"Planagum\u00e0","year":"2015","journal-title":"Brain J Neurol"},{"key":"10.1007\/s13311-021-01175-7_bib48","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/ana.24721","article-title":"Ephrin-B2 prevents N-methyl-D-aspartate receptor antibody effects on memory and neuroplasticity","volume":"80","author":"Planagum\u00e0","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-021-01175-7_bib49","first-page":"3144","article-title":"LGI1 antibodies alter Kv1.1 and AMPA receptors changing synaptic excitability, plasticity and memory","volume":"141","author":"Petit-Pedrol","year":"2018","journal-title":"Brain J. Neurol."},{"key":"10.1007\/s13311-021-01175-7_bib50","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-021-01175-7_bib51","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","article-title":"Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome","volume":"89","author":"Hennes","year":"2017","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01175-7_bib52","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clim.2010.11.013","article-title":"Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases","volume":"138","author":"Di Pauli","year":"2011","journal-title":"Clin Immunol Orlando Fla"},{"key":"10.1007\/s13311-021-01175-7_bib53","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-021-01175-7_bib54","doi-asserted-by":"crossref","first-page":"102109","DOI":"10.1016\/j.msard.2020.102109","article-title":"Beneficial effects of intravenous immunoglobulin as an add-on therapy to azathioprine for NMO-IgG-seropositive neuromyelitis optica spectrum disorders","volume":"42","author":"Lim","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1007\/s13311-021-01175-7_bib55","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01175-7_bib56","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/ana.21916","article-title":"Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease","volume":"66","author":"Brilot","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-021-01175-7_bib57","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.12271","article-title":"Neuromyelitis optica: clinical features, immunopathogenesis and treatment","volume":"176","author":"Jarius","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1007\/s13311-021-01175-7_bib58","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s12264-015-1552-6","article-title":"Experimental models of neuromyelitis optica: current status, challenges and future directions","volume":"31","author":"Li","year":"2015","journal-title":"Neurosci Bull"},{"key":"10.1007\/s13311-021-01175-7_bib59","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/BF00686201","article-title":"Experimental allergic encephalomyelitis: the balance between encephalitogenic T lymphocytes and demyelinating antibodies determines size and structure of demyelinated lesions","volume":"75","author":"Lassmann","year":"1988","journal-title":"Acta Neuropathol (Berl)"},{"key":"10.1007\/s13311-021-01175-7_bib60","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12974-016-0577-8","article-title":"Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid","volume":"13","author":"Marignier","year":"2016","journal-title":"J Neuroinflammation"},{"key":"10.1007\/s13311-021-01175-7_bib61","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00401-016-1559-8","article-title":"Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen","volume":"132","author":"Kinzel","year":"2016","journal-title":"Acta Neuropathol (Berl)"},{"key":"10.1007\/s13311-021-01175-7_bib62","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4103\/aian.AIAN_365_19","article-title":"Plasma exchange as a first line therapy in acute attacks of neuromyelitis optica spectrum disorders","volume":"22","author":"Kumawat","year":"2019","journal-title":"Ann Indian Acad Neurol"},{"key":"10.1007\/s13311-021-01175-7_bib63","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1002\/acn3.51203","article-title":"Effect of plasma exchange in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis","volume":"7","author":"Kosiyakul","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1007\/s13311-021-01175-7_bib64","first-page":"1324","article-title":"Lack of cross-species sensitization between skin allo- and xenotransplants in mice","volume":"26","author":"Vizler","year":"1994","journal-title":"Transplant Proc"},{"key":"10.1007\/s13311-021-01175-7_bib65","first-page":"257","article-title":"Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles","volume":"49","author":"Vincent","year":"1982","journal-title":"Clin Exp Immunol"},{"key":"10.1007\/s13311-021-01175-7_bib66","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3988\/jcn.2012.8.3.161","article-title":"Incidence of thymoma in myasthenia gravis: a systematic review","volume":"8","author":"Mao","year":"2012","journal-title":"J Clin Neurol Seoul Korea"},{"key":"10.1007\/s13311-021-01175-7_bib67","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/joim.12163","article-title":"Pathogenic immune mechanisms at the neuromuscular synapse: the role of specific antibody-binding epitopes in myasthenia gravis","volume":"275","author":"Huijbers","year":"2014","journal-title":"J Intern Med"},{"key":"10.1007\/s13311-021-01175-7_bib68","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJM197805182982004","article-title":"Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation","volume":"298","author":"Drachman","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-021-01175-7_bib69","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1749-6632.1987.tb51301.x","article-title":"The membrane attack complex of complement at the endplate in myasthenia gravis","volume":"505","author":"Engel","year":"1987","journal-title":"Ann N Y Acad Sci"},{"key":"10.1007\/s13311-021-01175-7_bib70","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1056\/NEJM198209233071301","article-title":"Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis","volume":"307","author":"Drachman","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-021-01175-7_bib71","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3109\/08916934.2011.622015","article-title":"Myasthenogenicity of the main immunogenic region and endogenous muscle nicotinic acetylcholine receptors","volume":"45","author":"Luo","year":"2012","journal-title":"Autoimmunity"},{"key":"10.1007\/s13311-021-01175-7_bib72","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1212\/WNL.55.1.7","article-title":"Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"55","author":"Gronseth","year":"2000","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01175-7_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008111.pub2","article-title":"Thymectomy for non-thymomatous myasthenia gravis","author":"Cea","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1007\/s13311-021-01175-7_bib74","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primer"},{"key":"10.1007\/s13311-021-01175-7_bib75","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-021-01175-7_bib76","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1007\/s13311-021-01175-7_bib77","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1084\/jem.168.1.127","article-title":"Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q","volume":"168","author":"Bindon","year":"1988","journal-title":"J Exp Med"},{"key":"10.1007\/s13311-021-01175-7_bib78","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-021-01175-7_bib79","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1007\/s13311-021-01175-7_bib80","article-title":"Efficacy and safety of rozanolixizumab in moderate-to-severe generalised myasthenia gravis: A phase 2 RCT","author":"Bril","year":"2020","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01175-7_bib81","doi-asserted-by":"crossref","first-page":"15314","DOI":"10.1038\/ncomms15314","article-title":"Engineered clearing agents for the selective depletion of antigen-specific antibodies","volume":"8","author":"Devanaboyina","year":"2017","journal-title":"Nat Commun"},{"key":"10.1007\/s13311-021-01175-7_bib82","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.ymthe.2020.11.017","article-title":"Selective depletion of antigen-specific antibodies for the treatment of demyelinating disease","volume":"29","author":"Sun","year":"2021","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-021-01175-7_bib83","doi-asserted-by":"crossref","first-page":"462","DOI":"10.4049\/jimmunol.171.1.462","article-title":"Rat and Human Myelin Oligodendrocyte Glycoproteins Induce Experimental Autoimmune Encephalomyelitis by Different Mechanisms in C57BL\/6 Mice","volume":"171","author":"Oliver","year":"2003","journal-title":"J Immunol"},{"key":"10.1007\/s13311-021-01175-7_bib84","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/jim-2019-001126","article-title":"CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease","volume":"68","author":"Rosenthal","year":"2020","journal-title":"J Investig Med"},{"key":"10.1007\/s13311-021-01175-7_bib85","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol"},{"issue":"194","key":"10.1007\/s13311-021-01175-7_bib86","first-page":"4595","article-title":"FcRn: the architect behind the immune and nonimmune functions of IgG and albumin","volume":"1950","author":"Pyzik","year":"2015","journal-title":"J Immunol Baltim Md"},{"key":"10.1007\/s13311-021-01175-7_bib87","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/bloodadvances.2018020644","article-title":"Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b\/2 studies","volume":"2","author":"R\u00f6th","year":"2018","journal-title":"Blood Adv"},{"key":"10.1007\/s13311-021-01175-7_bib88","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-021-01175-7_bib89","doi-asserted-by":"crossref","unstructured":"Fujihara, K. et al. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol. - Neuroimmunol. Neuroinflammation. 2020;7.","DOI":"10.1212\/NXI.0000000000000841"},{"key":"10.1007\/s13311-021-01175-7_bib90","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1007\/s13311-021-01175-7_bib91","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195909","article-title":"Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action","volume":"13","author":"Sheridan","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1007\/s13311-021-01175-7_bib92","unstructured":"Alexion announces positive topline results from phase 3 study of ULTOMIRIS\u00ae (ravulizumab-cwvz) in adults with generalized myasthenia gravis (gMG) | Alexion Pharmaceuticals, Inc. https:\/\/ir.alexion.com\/news-releases\/news-release-details\/alexion-announces-positive-topline-results-phase-3-study. Accessed 1 Nov 2021."},{"key":"10.1007\/s13311-021-01175-7_bib93","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.3389\/fimmu.2019.03052","article-title":"Antagonism of the neonatal Fc receptor as an emerging treatment for myasthenia gravis","volume":"10","author":"Gable","year":"2020","journal-title":"Front Immunol"},{"key":"10.1007\/s13311-021-01175-7_bib94","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1038\/s41598-018-23481-5","article-title":"In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor","volume":"8","author":"Seijsing","year":"2018","journal-title":"Sci Rep"},{"key":"10.1007\/s13311-021-01175-7_bib95","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/cpt.1276","article-title":"M281, an anti-FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first-in-human study","volume":"105","author":"Ling","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1007\/s13311-021-01175-7_bib96","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/bloodadvances.2020002003","article-title":"Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia","volume":"4","author":"Robak","year":"2020","journal-title":"Blood Adv"},{"key":"10.1007\/s13311-021-01175-7_bib97","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","article-title":"Targeting FcRn for immunomodulation: benefits, risks, and practical considerations","volume":"146","author":"Peter","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1007\/s13311-021-01175-7_bib98","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fimmu.2019.00033","article-title":"The expanding field of secondary antibody deficiency: causes, diagnosis, and management","volume":"10","author":"Patel","year":"2019","journal-title":"Front Immunol"},{"key":"10.1007\/s13311-021-01175-7_bib99","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/bmb\/ldn034","article-title":"The immunodeficiency of chronic lymphocytic leukaemia","volume":"87","author":"Hamblin","year":"2008","journal-title":"Br Med Bull"},{"key":"10.1007\/s13311-021-01175-7_bib100","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1034\/j.1600-065X.2000.17815.x","article-title":"Molecular basis of IgG subclass deficiency","volume":"178","author":"Pan","year":"2000","journal-title":"Immunol Rev"},{"key":"10.1007\/s13311-021-01175-7_bib101","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1007\/s13311-021-01175-7_bib102","doi-asserted-by":"crossref","unstructured":"Johswich, K. Innate immune recognition and inflammation in Neisseria meningitidis infection. Pathog Dis. 2017;75.","DOI":"10.1093\/femspd\/ftx022"},{"key":"10.1007\/s13311-021-01175-7_bib103","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.1128\/IAI.72.10.5807-5813.2004","article-title":"Limited role of antibody in clearance of streptococcus pneumoniae in a murine model of colonization","volume":"72","author":"McCool","year":"2004","journal-title":"Infect Immun"},{"key":"10.1007\/s13311-021-01175-7_bib104","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","article-title":"Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections","volume":"26","author":"Long","year":"2020","journal-title":"Nat Med"},{"key":"10.1007\/s13311-021-01175-7_bib105","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1471-4159.2002.00840.x","article-title":"Expression of the neonatal Fc receptor (FcRn) at the blood\u2013brain barrier","volume":"81","author":"Schlachetzki","year":"2002","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-021-01175-7_bib106","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.brainres.2013.08.035","article-title":"Efflux of monoclonal antibodies from rat brain by neonatal Fc receptor, FcRn","volume":"1534","author":"Cooper","year":"2013","journal-title":"Brain Res"},{"key":"10.1007\/s13311-021-01175-7_bib107","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0165-5728(01)00242-9","article-title":"Mediated efflux of IgG molecules from brain to blood across the blood\u2013brain barrier","volume":"114","author":"Zhang","year":"2001","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-021-01175-7_bib108","doi-asserted-by":"crossref","first-page":"502","DOI":"10.4161\/mabs.27765","article-title":"The effect of the neonatal Fc receptor on human IgG biodistribution in mice","volume":"6","author":"Chen","year":"2014","journal-title":"MAbs"},{"key":"10.1007\/s13311-021-01175-7_bib109","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1021\/mp300214k","article-title":"Investigation of the role of Fc\u03b3R and FcRn in mAb distribution to the brain","volume":"10","author":"Abuqayyas","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1007\/s13311-021-01175-7_bib110","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1038\/s41598-020-60438-z","article-title":"Antibody transcytosis across brain endothelial-like cells occurs nonspecifically and independent of FcRn","volume":"10","author":"Ruano-Salguero","year":"2020","journal-title":"Sci Rep"},{"key":"10.1007\/s13311-021-01175-7_bib111","doi-asserted-by":"crossref","unstructured":"Collins, J. et al. RVT-1401, A novel anti-FcRn monoclonal antibody, is well tolerated in healthy subjects and reduces plasma IgG following subcutaneous or intravenous administration (P5.2\u2013079). Neurology. 2019;92.","DOI":"10.1212\/WNL.92.15_supplement.P5.2-079"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01175-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-021-01175-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923010991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923010991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01175-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:59:38Z","timestamp":1761807578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923010991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":111,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1878747923010991"],"URL":"https:\/\/doi.org\/10.1007\/s13311-021-01175-7","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neonatal Fc Receptor\u2013Targeted Therapies in Neurology","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-021-01175-7","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The authors. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}